Please use this identifier to cite or link to this item:
|Title:||Outbreak of infections due to kpc-2-producing klebsiella pneumoniae in a hospital in Crete (Greece)||Authors:||Maltezou, Helena C.
Vatopoulos, Alkiviadis C.
|Major Field of Science:||Medical and Health Sciences||Field Category:||Clinical Medicine||Keywords:||KPC;Carbapenemase;Resistance;Nosocomial outbreak;Klebsiella pneumoniae;Tigecycline;Colistin||Issue Date:||Mar-2009||Source:||Journal of Infection, 2009, vol. 58, no. 3, pp. 213-219||Volume:||58||Issue:||3||Start page:||213||End page:||219||Journal:||Journal of Infection||Abstract:||Starting in May 2007, an ongoing outbreak of infections due to carbapenem resistant KPC-2-producing Klebsiella pneumoniae occurred in a tertiary care hospital in Crete (Greece). The outbreak involved 22 patients, none of whom had travelled in a country with known high prevalence of such isolates. KPC-producing K. pneumoniae strains were mainly isolated from patients admitted in the Intensive Care Unit, on mechanical ventilation, with prolonged hospitalization, prolonged administration of antibiotics, and prolonged administration of carbapenems. Clinical diagnoses were: pneumonia (62% of cases), surgical site infection (19%), bacteremia (9.5%), urinary tract infection (4.7%), and peritonitis (4.7%). Overall, 61 KPC-producing K. pneumoniae isolates were recovered, mainly from the respiratory tract (59.1%), catheter tip (22.7%), surgical site (18.2%), and blood (18.2%). Among 16 patients for whom therapeutic data were available, 14 (87.5%) were treated with a combination of colistin and/or tigecycline and/or garamycin. Clinical failure was noted in 22.2% of 18 patients available for assessment of clinical outcome, and microbiologic failure in 87.5% of 8 patients available for assessment of microbiologic outcome. In conclusion, an outbreak of KPC-producing K. pneumoniae infections has occurred in a tertiary care hospital in Greece, with significant associated morbidity and mortality. Prospective studies are required to evaluate the available therapeutic options for these infections. Our efforts should focus on rational use of available antibiotics, enhancement of infection control measures, and implementation of active antibiotic resistance surveillance.||URI:||http://ktisis.cut.ac.cy/handle/10488/6974||ISSN:||0163-4453||DOI:||10.1016/j.jinf.2009.01.010||Rights:||© Elsevier||Type:||Article||Affiliation:||Hellenic Centre for Disease Control and Prevention||Affiliation :||Hellenic Centre for Disease Control and Prevention
National School of Public Health
Venizeleio General Hospital
|Appears in Collections:||Άρθρα/Articles|
checked on Apr 21, 2021
WEB OF SCIENCETM
checked on Apr 22, 2021
checked on May 6, 2021
Items in KTISIS are protected by copyright, with all rights reserved, unless otherwise indicated.